← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksAVBPRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

AVBP logoArriVent BioPharma, Inc. Common Stock (AVBP) Revenue History

Annual and quarterly revenue from 2021 to 2025

TTM Revenue
$0
0
YoY Growth
-
Latest Quarter
$0
Q4 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$0 (0)
Highest Quarter$0 ()

Loading revenue history...

AVBP Revenue Growth

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$0 (0)

Download Historical Data

5 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

AVBP Revenue Analysis (2021–2025)

As of May 8, 2026, ArriVent BioPharma, Inc. Common Stock (AVBP) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.

Looking at the longer-term picture, AVBP's historical revenue data shows various trends over time.

When compared to Healthcare sector peers including RCUS (+67.4% YoY), TPVG, and KYMR (-12.6% YoY). Compare AVBP vs RCUS →

AVBP Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
AVBP logoAVBPCurrent$0---
RCUS logoRCUS$247M+67.4%+25.9%-156.3%
TPVG logoTPVG$97M--77.9%
KYMR logoKYMR$39M-12.6%+2.9%-891.3%
TARS logoTARS$451M+129.0%--15.7%
Best in groupLowest in group

AVBP Historical Revenue Data (2021–2025)

Showing 5 of 5 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2025$0-$0-$0-
2024$0-$0-$-94,308,000-
2023$0-$0-$-74,590,000-
2022$0-$0-$-36,906,000-
2021$0-$0-$-8,696,000-

See AVBP's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is AVBP Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare AVBP vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

AVBP — Frequently Asked Questions

Quick answers to the most common questions about buying AVBP stock.

Is AVBP's revenue growth accelerating or slowing?

AVBP TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is AVBP's long-term revenue growth rate?

ArriVent BioPharma, Inc. Common Stock's 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is AVBP's revenue distributed by segment?

AVBP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2021-2025 are available for download. Segment mix reveals concentration and diversification trends.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

AVBP Revenue Over Time (2021–2025)